Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Mallinckrodt
Boehringer Ingelheim
McKesson
Dow

Last Updated: January 25, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Delamanid


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Delamanid?

Delamanid is an investigational drug.

There have been 19 clinical trials for Delamanid. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2020.

The most common disease conditions in clinical trials are Tuberculosis, Tuberculosis, Multidrug-Resistant, and Tuberculosis, Pulmonary. The leading clinical trial sponsors are Otsuka Pharmaceutical Development & Commercialization, Inc., National Institute of Allergy and Infectious Diseases (NIAID), and Harvard Medical School.

There are nine US patents protecting this investigational drug and two hundred and eighty-nine international patents.

Recent Clinical Trials for Delamanid
TitleSponsorPhase
Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TBDe La Salle Health Sciences Institute, PhilippinesPhase 2
Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TBHarvard Medical SchoolPhase 2
Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TBHarvard Medical School (HMS and HSDM)Phase 2

See all Delamanid clinical trials

Clinical Trial Summary for Delamanid

Top disease conditions for Delamanid
Top clinical trial sponsors for Delamanid

See all Delamanid clinical trials

US Patents for Delamanid

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Delamanid ⤷  Try it Free Nitroimidazooxazine and nitroimidazooxazole analogues and their uses Global Alliance for TB Drug Development (New York, NY) ⤷  Try it Free
Delamanid ⤷  Try it Free Pharmaceutical composition achieving excellent absorbency of pharmacologically active substance Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP) ⤷  Try it Free
Delamanid ⤷  Try it Free Antituberculous composition comprising oxazole compounds Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP) ⤷  Try it Free
Delamanid ⤷  Try it Free Nitroimidazooxazines and their uses in anti-tubercular therapy Global Alliance for TB Drug Development (New York, NY) ⤷  Try it Free
Delamanid ⤷  Try it Free Imidazo [1,2-a]pyridine compounds, synthesis thereof, and methods of using same UNIVERSITY OF NOTRE DAME DU LAC (Notre Dame, IN) ⤷  Try it Free
Delamanid ⤷  Try it Free Combination therapy to treat Mycobacterium diseases SPERO TRINEM, INC. (Cambridge, MA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Delamanid

Drugname Country Document Number Estimated Expiration Related US Patent
Delamanid China CN107406386 2035-03-27 ⤷  Try it Free
Delamanid Eurasian Patent Organization EA201792154 2035-03-27 ⤷  Try it Free
Delamanid European Patent Office EP3275862 2035-03-27 ⤷  Try it Free
Delamanid Japan JP6776226 2035-03-27 ⤷  Try it Free
Delamanid Japan JPWO2016158737 2035-03-27 ⤷  Try it Free
Delamanid South Korea KR20170129898 2035-03-27 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Mallinckrodt
Boehringer Ingelheim
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.